Phase 1 Bladder Urothelial Carcinoma Clinical Trials
7 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–7 of 7 trials
Recruiting
Phase 1
A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder Cancer
Non-Muscle Invasive Bladder Urothelial CarcinomaRecurrent Non-Muscle Invasive Bladder Urothelial Carcinoma
University of Wisconsin, Madison80 enrolled6 locationsNCT05521698
Recruiting
Phase 1
Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
Locally Advanced Urothelial CarcinomaMetastatic Urothelial CarcinomaUnresectable Urothelial Carcinoma+1 more
Emory University32 enrolled1 locationNCT04878029
Recruiting
Phase 1
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
Urothelial Carcinoma BladderNon Muscle Invasive Bladder CancerNMIBC+3 more
Aura Biosciences55 enrolled17 locationsNCT05483868
Recruiting
Phase 1
Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer
Muscle-Invasive Bladder CarcinomaLocalized Muscle Invasive Bladder Urothelial Carcinoma
Shilpa Gupta, MD20 enrolled1 locationNCT05833867
Recruiting
Phase 1
IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer
Stage 0a Bladder Cancer AJCC v8Stage 0is Bladder Cancer AJCC v8Stage I Bladder Cancer AJCC v8+1 more
University of California, Davis30 enrolled1 locationNCT05843448
Recruiting
Phase 1Phase 2
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Triple-Negative Breast CancerNon-small Cell Lung CancerMetastatic Cancer+6 more
Hadassah Medical Organization3 enrolled1 locationNCT05296564
Recruiting
Phase 1
Irinotecan Liposomes Combined with Epirubicin in Recurrent Non-muscle Invasive Bladder Urothelium Carcinoma After Anthracyclines Treatment
Non-Muscle Invasive Bladder Urothelial Carcinoma
First Affiliated Hospital of Chongqing Medical University18 enrolled1 locationNCT06766266